Immunic (NASDAQ:IMUX) Announces Quarterly Earnings Results

Immunic (NASDAQ:IMUX) announced its quarterly earnings data on Friday. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.20), FiscalAI reports.

Immunic Price Performance

NASDAQ:IMUX traded down $0.27 during trading hours on Friday, reaching $7.52. The company had a trading volume of 105,145 shares, compared to its average volume of 297,743. Immunic has a 1-year low of $5.06 and a 1-year high of $17.43. The firm has a market cap of $102.57 million, a PE ratio of -1.72 and a beta of 1.48. The business’s 50 day moving average price is $8.80 and its 200-day moving average price is $11.51.

Key Headlines Impacting Immunic

Here are a few of the latest headlines about IMUX:

• Neutral Sentiment: Immunic is preparing to start its Phase 3 PROTECT-MS trial for progressive MS, with first-patient enrollment expected in the first half of 2027. The company also announced leadership appointments intended to support regulatory and commercial readiness. Article: Immunic reports third-quarter 2026 financial results and provides corporate update
• Negative Sentiment: Third-quarter results showed a $42.3 million net loss, with a loss of $0.99 per share—worse than the $0.79 loss analysts expected. Coverage cited higher expenses and the earnings miss as reasons for investor concern. Article: Immunic Q3 loss widens on higher expenses
• Negative Sentiment: Zacks Research downgraded Immunic from “strong-buy” to “hold,” adding to near-term caution ahead of the trial results. Article: Zacks Research stock recommendations

Analyst Ratings Changes

A number of analysts have recently weighed in on IMUX shares. Zacks Research lowered shares of Immunic from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Cantor Fitzgerald began coverage on shares of Immunic in a report on Friday, October 23rd. They set an “overweight” rating for the company. Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Ladenburg Thalmann & Co. Inc. upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Immunic in a report on Thursday, September 10th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.43.

About Immunic

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.